Similar to CD8+ TRM, Tregs were more quiescent than their tumor counterparts, as they expressed low levels of costimulatory molecules and lower enrichment for the T‐cell activation pathway (Fig. 5D). This evidence concerns the gene CD8A and neoplasm.